CRISPR Therapeutics AG (CRSP) FCF Margin (2016 - 2026)
CRISPR Therapeutics AG (CRSP) reported FCF Margin of 7503.5% for Q1 2026, down 124304.0% on a YoY basis from N/an in Q1 2025, and up 30.34% sequentially from 10771.99% in Q4 2025.
CRISPR Therapeutics AG (CRSP) FCF Margin (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG (CRSP) has 11 years of FCF Margin data on file, last reported at 7503.5% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 124304.0% year-over-year to 7503.5%; the trailing twelve-month figure through Mar 2026 stood at 9777.63% (down 896512.0% YoY), and the FY2025 full-year result was 9855.5%, down 947246.0% from the prior year.
- FCF Margin improved to 7503.5% in Q1 2026, from 10771.99% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 21633.13% in Q1 2024 to a low of 1842166.67% in Q4 2022.
- A 5-year average of 131981.19% and a median of 10150.22% in 2025 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin plunged 184142846 bps in 2022 and soared 184211893 bps in 2023, its largest moves.
- Tracing CRSP's FCF Margin over 5 years: stood at 1842166.67% in 2022, then soared by 100 bps to 47.73% in 2023, then slumped by 185 bps to 136.0% in 2024, then slumped by 7821 bps to 10771.99% in 2025, then surged by 30 bps to 7503.5% in 2026.
- Business Quant data shows CRSP's FCF Margin at 7503.5% in Q1 2026, 10771.99% in Q4 2025, and 9528.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CRISPR Therapeutics AG | 4.57 Bn | 2.12 Bn | - | -7,503.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7,503.50% |
| Dec 31, 2025 | -10,771.99% |
| Sep 30, 2025 | -9,528.46% |
| Jun 30, 2025 | -12,779.93% |
| Mar 31, 2025 | -6,260.46% |
| Dec 31, 2024 | -136.00% |
| Sep 30, 2024 | -17,796.01% |
| Jun 30, 2024 | -18,624.56% |
| Mar 31, 2024 | 21,633.13% |
| Dec 31, 2023 | -47.73% |
| Jun 30, 2023 | -187.45% |
| Mar 31, 2023 | 5.74% |
| Dec 31, 2022 | -1,842,166.67% |
| Sep 30, 2022 | -90,592.55% |
| Jun 30, 2022 | -101,929.11% |
| Mar 31, 2022 | -15,013.51% |
| Dec 31, 2021 | -738.20% |
| Sep 30, 2021 | -14,366.26% |
| Jun 30, 2021 | 86.64% |
| Mar 31, 2021 | -20,317.25% |